Objective This study examines the relationship between WDFY4 gene DNA methylation and clinical characteristics of rheumatoid arthritis (RA) through peripheral blood analysis. Methods Peripheral blood samples from 150 RA patients and 150 healthy controls were analyzed via targeted methylation sequencing. Generalized linear regression assessed associations between WDFY4 methylation haplotypes, CpG sites, and clinical markers, with adjustment for potential confounders. Results RA patients exhibited significantly reduced overall WDFY4 methylation levels compared to controls (0.865 ± 0.053 vs. 0.882 ± 0.043) (FDR P = 0.0088), with six specific CpG sites showing marked hypomethylation (FDR P < 0.05). Among the 22 identified haplotypes, five differed significantly between groups. Negative correlations were observed between WDFY4 methylation and anti-CCP antibodies (ACPA), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Conclusions WDFY4 methylation may critically influence RA pathogenesis and immunoinflammatory responses. Integrating WDFY4 methylation data with environmental factors, inflammatory markers (CRP/ESR), and autoantibodies (ACPA/RF) could enhance the understanding of RA pathophysiology and potentially aid in subgroup stratification.<Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec align="left" colname="c1" colnum="1" /> <colspec align="left" colname="c2" colnum="2" /> <tbody> <row> <entry nameend="c2" namest="c1"> Key Points • Targeted methylation sequencing revealed significant WDFY4 hypomethylation at specific CpG sites in RA patients versus controls. • WDFY4 methylation levels negatively correlated with RA autoantibodies and inflammatory markers, indicating its potential role in disease mechanisms. • Integrating WDFY4 methylation with clinical data improved RA and comorbidity diagnosis, with an AUC of 0.844 for predicting pulmonary fibrosis, highlighting its novel discriminative potential. </entry> </row> </tbody> </tgroup> </Table>

Epigenetic alterations in WDFY4 DNA methylation are linked to immunoinflammatory processes in rheumatoid arthritis: insights from a case–control study

期刊论文
发表日期：

2026年4月11日

查看全文

Zhen Liu,
Fan Yang,
Zhenglun Pan

摘要

Objective

This study examines the relationship between WDFY4 gene DNA methylation and clinical characteristics of rheumatoid arthritis (RA) through peripheral blood analysis.

Methods

Peripheral blood samples from 150 RA patients and 150 healthy controls were analyzed via targeted methylation sequencing. Generalized linear regression assessed associations between WDFY4 methylation haplotypes, CpG sites, and clinical markers, with adjustment for potential confounders.

Results

RA patients exhibited significantly reduced overall WDFY4 methylation levels compared to controls (0.865 ± 0.053 vs. 0.882 ± 0.043) (FDR P = 0.0088), with six specific CpG sites showing marked hypomethylation (FDR P < 0.05). Among the 22 identified haplotypes, five differed significantly between groups. Negative correlations were observed between WDFY4 methylation and anti-CCP antibodies (ACPA), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).

Conclusions

WDFY4 methylation may critically influence RA pathogenesis and immunoinflammatory responses. Integrating WDFY4 methylation data with environmental factors, inflammatory markers (CRP/ESR), and autoantibodies (ACPA/RF) could enhance the understanding of RA pathophysiology and potentially aid in subgroup stratification.

Key Points

• Targeted methylation sequencing revealed significant WDFY4 hypomethylation at specific CpG sites in RA patients versus controls.

• WDFY4 methylation levels negatively correlated with RA autoantibodies and inflammatory markers, indicating its potential role in disease mechanisms.

• Integrating WDFY4 methylation with clinical data improved RA and comorbidity diagnosis, with an AUC of 0.844 for predicting pulmonary fibrosis, highlighting its novel discriminative potential.